GlassScriptPhysician profile
Richard C Orris
NPI 1033186598
$22,336.28
in general payments reported to CMS, 2019-2025
62 companies · $3,379 in 2025
The $3,379 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,789 · 2020: $1,828 · 2021: $2,124 · 2022: $3,486 · 2023: $3,698 · 2024: $4,032 · 2025: $3,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $4.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,105.04 |
| Education | $4.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,727.82 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,063.03 | 2019-2025 | Breztri, Airsupra, Bevespi Aerosphere |
| Novo Nordisk INC | $1,813.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,695.32 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,216.77 | 2019-2025 | Jardiance, Stiolto Respimat |
| Lilly USA, LLC | $1,141.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $867.54 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $847.45 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Sanofi-Aventis U.S. LLC | $818.87 | 2019-2025 | |
| Amgen INC. | $777.59 | 2019-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $772.52 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $756.03 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $631.80 | 2019-2025 | Xarelto, Spravato |
| Abbott Laboratories | $611.10 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $516.36 | 2019-2025 | Xifaxan, Trulance, Relistor |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Orris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.